Led by a faculty team of specialty pharmacy and dermatology experts, this curriculum will provide targeted education to community pharmacists for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). The presentation will provide discussion around the connection between AD and AA, the role of Janus Kinase (JAK)-signal transducer activator of transcription pathways in the pathogenesis of AD and AA, the latest clinical trial data on emerging agents, racial and health disparities in patients with AA and AD, and the unique role of the pharmacist in providing education and obtaining prior authorization to medications. Utilizing video interviews with actual patients, you will gain greater awareness and empathy for the significant quality of life burden that patients who have these conditions encounter on a daily basis. This program has been thoughtfully crafted to be interactive and will include engaging discussions, valuable teaching points, and ample opportunity for Q&A with leading experts.
1. Explore the changing paradigm of AA and AD disease presentation and treatment approach.
2. Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.
3. Recognize the potential place in therapy and monitoring aspects for the emerging agents in AD and AA in order to effectively engage patients in shared decision-making for their treatment plan.
4. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.
Acknowledgement: This activity is presented by Boston University School of Medicine and The University of Rhode Island College of Pharmacy and is supported by and independent educational grant from Pfizer